pms-IRBESARTAN: Affected lot may contain pms-IRBESARTAN/HCTZ 150/12.5 mg tablets.
Brand(s)
Last updated
Summary
Product
pms-IRBESARTAN 150 mg Tablet
Issue
Health products - Contamination
What to do
Consult your healthcare provider prior to discontinuing use of the affected product, or if you have any health concerns.
Affected products
| Brand | Product Name | Market Authorization | Dosage Form | Strength | Lot Number |
|---|---|---|---|---|---|
| Pharmascience Inc. | pms-IRBESARTAN | DIN 02317079 | Tablet | 150 mg | 667278 |
Issue
The affected lot may contain pms-IRBESARTAN/HCTZ 150/12.5 mg tablets.
What you should do
- Verify whether your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product, or if you have any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Pharmascience Inc.
6111 avenue Royalmount, suite 100, Montréal
QC H4P 2T4
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type II
Recall date
Identification number
RA-82479
Get notified
Receive emails about new and updated recall and safety alerts.